What this article helps you consider
- Begin with the product and the decision
- Select attributes that can change
- Make batches and packaging representative
Begin with the product and the decision
Before placing samples in a chamber, define the dosage form, strengths, formulation, intended storage statement, container closure system and proposed shelf life. Identify whether the decision concerns initial registration, a formulation comparison, a packaging change or an extension of an existing shelf life. These decisions require different evidence packages. A screening experiment can rank prototypes without providing the representative batch evidence needed for a commercial shelf-life claim.
For medicines, identify the guidance adopted by the target authority and the relevant submission pathway. For nutraceuticals and natural products, establish the applicable food or supplement requirements separately. Pharmaceutical stability principles can inform study design, but their use does not automatically make a food product subject to pharmaceutical registration requirements. The consolidated ICH Q1 document was listed by FDA as draft guidance when checked for this collection; draft recommendations should not be described as implemented requirements. R01R03R24
Select attributes that can change
An assay-only programme can miss a failing product. A tablet may retain its active content while its dissolution slows. A liquid may remain chemically acceptable while precipitation affects dose delivery. A botanical product may meet one marker specification while its broader fingerprint changes. Select physical, chemical, microbiological and functional measurements according to plausible failure mechanisms.
For a moisture-sensitive chewable, a useful development panel might include active content, relevant degradation products, water content, texture or breaking force, appearance and microbiological quality where appropriate. Sampling should capture the product actually supplied to the user. A composite assay cannot establish unit-to-unit uniformity, and testing a liquid after ideal laboratory mixing may conceal difficulties with the labelled shaking instruction.
Make batches and packaging representative
Use batches that represent the proposed composition, process and material controls. Record differences between development and intended commercial manufacture so their significance can be assessed. Select the marketed packaging early enough to generate relevant evidence. Unprotected samples provide useful mechanistic information but cannot substitute for stability data in the proposed commercial pack.
Different fill counts, headspaces or closure systems can change exposure. Bracketing and matrixing reduce testing only where the scientific justification and applicable guidance support them. An assumption that the largest bottle is always the worst case is unreliable because headspace, closure performance and frequency of opening may interact. R01R02
Use accelerated studies for the questions they can answer
Elevated temperature and humidity help identify vulnerabilities and compare options. They do not create a universal conversion between a few months in a chamber and several years on a shelf. A formulation can change its physical state or degradation pathway under severe conditions. In that situation, a simple acceleration model may no longer describe real storage.
Select long-term and accelerated conditions for the product, pack and intended markets. Add photostability, temperature cycling, transport or in-use studies when their questions are relevant. For a multidose bottle, repeated opening may create an exposure that a continuously sealed sample never experiences. These studies complement the core programme rather than replace it.
Interpret trends before the limit is crossed
Review individual batches, variability and the relationship between attributes. A rising impurity accompanied by a falling assay suggests a different investigation from an isolated analytical shift. Where regression is appropriate, document model assumptions and uncertainty. Do not extrapolate a shelf life solely from the point where an average line meets a limit; the regulatory evaluation and relevant confidence bounds also matter. R02
The illustration illustrates why two batches with acceptable results today may have different remaining margins. The lines are invented for explanation and establish no shelf life. In practice, the decision must account for every relevant attribute, including those that cannot be represented by a simple linear model.
Invented teaching data; not Stabicon experimental results. No shelf life or confidence bounds are calculated.
A practical development example
Consider a vitamin tablet that remains within assay limits but softens in a bottle during development. Compare the original pack with an alternative closure or desiccant configuration while tracking moisture and physical performance. If the alternative reduces moisture uptake without introducing another problem, it becomes a candidate for confirmation in a representative programme. The experiment supports a packaging decision; it does not, by itself, justify a new expiry date.
Stabicon can help connect protocol design, controlled storage and analytical evaluation so that stability findings inform formulation and packaging decisions as well as shelf-life assessment.
References & further reading
Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.
- R01ICH Q1A R2 Stability Testing of New Drug Substances and Products
Final guideline, 2003. Pharmaceutical scope; apply target-authority requirements.
- R02ICH Q1E Evaluation for Stability Data
Final guideline, 2003. Evaluation and justified extrapolation of stability data.
- R03ICH Q1D Bracketing and Matrixing Designs for Stability Testing
Final guideline, 2002. Reduced designs require scientific justification.
- R24FDA Q1 Stability Testing of Drug Substances and Drug Products
Draft guidance, June 2025, as listed when checked. Not for implementation.
From insight to a defined programme
Bring your next technical question.
Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.
Discuss this topic with Stabicon






